Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 1/2022

01-02-2022 | SARS-CoV-2 | Brief Report

SARS-CoV-2 seroepidemiological study in healthcare workers and discordant results using seven different diagnostic methods

Authors: Elizabeth-Barbara Tatsi, Charilaos Dellis, Evangelia Petridou, Kirkira Banou, Levantia Zachariadou, Vassiliki Syriopoulou, Athanasios Michos

Published in: Infection | Issue 1/2022

Login to get access

Abstract

The aim of the study was to access the SARS-CoV-2 antibody seroprevalence in healthcare workers (HCWs) of a tertiary pediatric hospital after the first wave of the pandemic and to compare the results among seven commercially available antibody detection assays, including chemiluminescence (CMIA), electroluminescence (ECLIA), Εnzyme-Linked Immunosorbent Assay (ELISA), and rapid immunochromatography (RIC). SARS-CoV-2 antibody detection was performed in serum samples of 1216 HCWs, using a reference CMIA assay and 8/1216 (0.66%) were detected positive. Positive serum samples were further tested with other assays; however, only one sample was positive by all tests. The rest 7 cases were negative with ECLIA and ELISA and gave discordant results with RIC test. Six months later, new serum samples of seropositive HCWs were analyzed with the same 7 tests, with inconsistent results again. Identification of reliable SARS-CoV-2 antibody tests is important to determine the actual number of past infections, the duration of antibodies, and guide public health decisions.
Literature
1.
WHO (2020) 'New-type coronavirus causes pneumonia in Wuhan: expert, Xinhua, China'; WHO. Coronavirus diseases (COVID-19), weekly operational update on COVID-19 (2020).
2.
Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang DY, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7:11.PubMedPubMedCentral
3.
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782–93.CrossRef
4.
Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schunemannauthors C-SURGEs HJ. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020;395:1973–87.CrossRef
5.
De Vito A, Geremia N, Fiore V, Princic E, Babudieri S, Madeddu G. Clinical features, laboratory findings and predictors of death in hospitalized patients with COVID-19 in Sardinia. Italy Eur Rev Med Pharmacol Sci. 2020;24:7861–8.PubMed
6.
Vaira LA, Hopkins C, Salzano G, Petrocelli M, Melis A, Cucurullo M, Ferrari M, Gagliardini L, Pipolo C, Deiana G, Fiore V, De Vito A, Turra N, Canu S, Maglio A, Serra A, Bussu F, Madeddu G, Babudieri S, Giuseppe Fois A, Pirina P, Salzano FA, De Riu P, Biglioli F, De Riu G. Olfactory and gustatory function impairment in COVID-19 patients: Italian objective multicenter-study. Head Neck. 2020;42:1560–9.CrossRef
7.
Guarneri C, Rullo EV, Pavone P, Berretta M, Ceccarelli M, Natale A, Nunnari G. Silent COVID-19: what your skin can reveal. Lancet Infect Dis. 2021;21:24–5.CrossRef
8.
9.
Shields A, Faustini SE, Perez-Toledo M, Jossi S, Aldera E, Allen JD, Al-Taei S, Backhouse C, Bosworth A, Dunbar LA, Ebanks D, Emmanuel B, Garvey M, Gray J, Kidd IM, McGinnell G, McLoughlin DE, Morley G, O’Neill J, Papakonstantinou D, Pickles O, Poxon C, Richter M, Walker EM, Wanigasooriya K, Watanabe Y, Whalley C, Zielinska AE, Crispin M, Wraith DC, Beggs AD, Cunningham AF, Drayson MT, Richter AG. SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study. Thorax. 2020;75:1089–94.CrossRef
10.
Iversen K, Bundgaard H, Hasselbalch RB, Kristensen JH, Nielsen PB, Pries-Heje M, Knudsen AD, Christensen CE, Fogh K, Norsk JB, Andersen O, Fischer TK, Jensen CAJ, Larsen M, Torp-Pedersen C, Rungby J, Ditlev SB, Hageman I, Mogelvang R, Hother CE, Gybel-Brask M, Sorensen E, Harritshoj L, Folke F, Sten C, Benfield T, Nielsen SD, Ullum H. Risk of COVID-19 in health-care workers in Denmark: an observational cohort study. Lancet Infect Dis. 2020;20:1401–8.CrossRef
11.
Hueston L, Kok J, Guibone A, McDonald D, Hone G, Goodwin J, Carter I, Basile K, Sandaradura I, Maddocks S, Sintchenko V, Gilroy N, Chen S, Dwyer DE, O’Sullivan MVN. The Antibody Response to SARS-CoV-2 Infection. Open Forum Infect Dis. 2020;7:ofaa387.CrossRef
12.
Gundlapalli AV, Salerno RM, Brooks JT, Averhoff F, Petersen LR, McDonald LC, Iademarco MF, Response CC-. SARS-CoV-2 serologic assay needs for the next phase of the US COVID-19 pandemic response. Open Forum Infect Dis. 2021;8:ofaa555.CrossRef
13.
Yong SEF, Anderson DE, Wei WE, Pang J, Chia WN, Tan CW, Teoh YL, Rajendram P, Toh M, Poh C, Koh VTJ, Lum J, Suhaimi NM, Chia PY, Chen MI, Vasoo S, Ong B, Leo YS, Wang L, Lee VJM. Connecting clusters of COVID-19: an epidemiological and serological investigation. Lancet Infect Dis. 2020;20:809–15.CrossRef
14.
L’Huillier AG, Meyer B, Andrey DO, Arm-Vernez I, Baggio S, Didierlaurent A, Eberhardt CS, Eckerle I, Grasset-Salomon C, Huttner A, Posfay-Barbe KM, Royo IS, Pralong JA, Vuilleumier N, Yerly S, Siegrist CA, Kaiser L, Centre Geneva, for Emerging Viral D, . Antibody persistence in the first six months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study. Clin Microbiol Infect. 2021;27:784-e1.CrossRef
15.
Houlihan CF, Beale R. The complexities of SARS-CoV-2 serology. Lancet Infect Dis. 2020;20:1350–1.CrossRef
16.
Goldblatt D, Johnson M, Falup-Pecurariu O, Ivaskeviciene I, Spoulou V, Tamm E, Wagner M, Zar HJ, Bleotu L, Ivaskevicius R, Papadatou I, Jogi P, Lischka J, Franckling-Smith Z, Isarova D, Grandjean L, Zavadska D. Cross sectional prevalence of SARS-CoV-2 antibodies in health care workers in paediatric facilities in eight Countries. J Hosp Infect. 2021;110:60–6.CrossRef
17.
Yong G, Yi Y, Tuantuan L, Xiaowu W, Xiuyong L, Ang L, Mingfeng H. Evaluation of the auxiliary diagnostic value of antibody assays for the detection of novel coronavirus (SARS-CoV-2). J Med Virol. 2020;92:1975–9.CrossRef
18.
Dacosta-Urbieta A, Rivero-Calle I, Pardo-Seco J, Redondo-Collazo L, Salas A, Gomez-Rial J, Martinon-Torres F. Seroprevalence of SARS-CoV-2 among pediatric healthcare workers in Spain. Front Pediatr. 2020;8:547.CrossRef
19.
Amendola A, Tanzi E, Folgori L, Barcellini L, Bianchi S, Gori M, Cammi G, Albani E, Zuccotti GV. Low seroprevalence of SARS-CoV-2 infection among healthcare workers of the largest children hospital in Milan during the pandemic wave. Infect Control Hosp Epidemiol. 2020;41:1468–9.CrossRef
20.
Psichogiou M, Karabinis A, Pavlopoulou ID, Basoulis D, Petsios K, Roussos S, Pratikaki M, Jahaj E, Protopapas K, Leontis K, Rapti V, Kotanidou A, Antoniadou A, Poulakou G, Paraskevis D, Sypsa V, Hatzakis A. Antibodies against SARS-CoV-2 among health care workers in a country with low burden of COVID-19. PLoS One. 2020;15:e0243025.CrossRef
21.
Venugopal U, Jilani N, Rabah S, Shariff MA, Jawed M, Mendez Batres A, Abubacker M, Menon S, Pillai A, Shabarek N, Kasubhai M, Dimitrov V, Menon V. SARS-CoV-2 seroprevalence among health care workers in a New York City hospital: a cross-sectional analysis during the COVID-19 pandemic. Int J Infect Dis. 2021;102:63–9.CrossRef
22.
Stefanelli P, Bella A, Fedele G, Pancheri S, Leone P, Vacca P, Neri A, Carannante A, Fazio C, Benedetti E, Fiore S, Fabiani C, Simmaco M, Santino I, Zuccali MG, Bizzarri G, Magnoni R, Benetollo PP, Merler S, Brusaferro S, Rezza G, Ferro A. Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study. Clin Microbiol Infect. 2020;27:633-e1.PubMedPubMedCentral
23.
Orner EP, Rodgers MA, Hock K, Tang MS, Taylor R, Gardiner M, Olivo A, Fox A, Prostko J, Cloherty G, Farnsworth CW. Comparison of SARS-CoV-2 IgM and IgG seroconversion profiles among hospitalized patients in two US cities. Diagn Microbiol Infect Dis. 2020;99:115300.CrossRef
24.
Wilkins JT, Gray EL, Wallia A, Hirschhorn LR, Zembower TR, Ho J, Kalume N, Agbo O, Zhu A, Rasmussen-Torvik LJ, Khan SS, Carnethon M, Huffman M, Evans CT. Seroprevalence and correlates of SARS-CoV-2 antibodies in health care workers in Chicago. Open Forum Infect Dis. 2021;8:582.CrossRef
25.
Catry E, Jacqmin H, Dodemont M, Saad Albichr I, Lardinois B, de Fays B, Delaere B, Closset M, Laurent T, Denis O, Galanti L, Mullier F, Huang TD. Analytical and clinical evaluation of four commercial SARS-CoV-2 serological immunoassays in hospitalized patients and ambulatory individuals. J Virol Methods. 2021;289:114060.CrossRef
26.
Harley K, Gunsolus IL. Comparison of the Clinical Performances of the Abbott Alinity IgG, Abbott Architect IgM, and Roche Elecsys Total SARS-CoV-2 Antibody Assays. J Clin Microbiol. 2020;59:e02104-20.CrossRef
27.
Manalac J, Yee J, Calayag K, Nguyen L, Patel PM, Zhou D, Shi RZ. Evaluation of Abbott anti-SARS-CoV-2 CMIA IgG and Euroimmun ELISA IgG/IgA assays in a clinical lab. Clin Chim Acta. 2020;510:687–90.CrossRef
28.
29.
Jones HE, Mulchandani R, Taylor-Phillips S, Ades AE, Shute J, Perry KR, Chandra NL, Brooks T, Charlett A, Hickman M, Oliver I, Kaptoge S, Danesh J, Di Angelantonio E, Wyllie D, Compare study investigators E-Hi. Accuracy of four lateral flow immunoassays for anti SARS-CoV-2 antibodies: a head-to-head comparative study. EBioMedicine. 2021;68:103414.CrossRef
30.
Mathur G, Mathur S. Antibody testing for COVID-19. Am J Clin Pathol. 2020;154:1–3.CrossRef
Metadata
Title
SARS-CoV-2 seroepidemiological study in healthcare workers and discordant results using seven different diagnostic methods
Authors
Elizabeth-Barbara Tatsi
Charilaos Dellis
Evangelia Petridou
Kirkira Banou
Levantia Zachariadou
Vassiliki Syriopoulou
Athanasios Michos
Publication date
01-02-2022
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 1/2022
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-021-01653-2

Other articles of this Issue 1/2022

Infection 1/2022 Go to the issue

Original Paper

Key summary of German national treatment guidance for hospitalized COVID-19 patients

Original Paper

COVID-19 in young and middle-aged adults: predictors of poor outcome and clinical differences

Original Paper

Relationship between serotypes, disease characteristics and 30-day mortality in adults with invasive pneumococcal disease

Review

Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?

Original Paper

A bacteraemia risk prediction model: development and validation in an emergency medicine population

Original Paper

A cost of illness study of COVID-19 patients and retrospective modelling of potential cost savings when administering remdesivir during the pandemic “first wave” in a German tertiary care hospital
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits